Lamivudine for hepatitis B in liver transplantation: A single-center experience

Transplantation

Volumn 69, Issue 7, 2000, Pages 1403-1407

  Malkan, Geeta ^a   Cattral, Mark S ^a,b   Humar, Atul ^a   Al Asghar, Hamad ^a   Greig, Paul D ^a   Hemming, Alan W ^a   Levy, Gary A ^a   Lilly, Les B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; OKT 3; PREDNISONE; STEROID; VIRUS DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT REJECTION; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; VIRUS REPLICATION;

EID: 0034655833     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200004150-00033     Document Type: Article

References (30)

1. Maynard JE. Hepatitis B: Global importance and need for control. Vaccine 1990; 8 (suppl 1): S18.
2. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493.
3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129.
4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
5. Lake JR. Should liver transplantation be performed for patients with chronic hepatitis B? Yes! Liver Transplant Surg 1995; 1: 260.
6. Dickson RC. Management of posttransplantation viral hepatitis - hepatitis B. Liver Transplant Surg 1998; 4(Suppl): S73.
7. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358.
8. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327.
9. Lowell JA, Burgess S, Shenoy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis B Immunoglobulin [Letter]. Lancet 1996; 347: 480.
10. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27(1): 254.
11. Tyrell DLJ, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 1993; 18: 112A.
12. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′ 3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88: 8495.
13. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for hepatitis B infection. N Engl J Med 1995; 333: 1657.
14. Lai CL, Chien RN, Leung NWY, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61.
15. Benhamou Y, Dubin E, Luel-Fabiani F, Poynard T, Huraux JM, Katlama C. Efficacy of lamivudine on replication of hepatitis B in HIV infected patients. Lancet 1995; 345: 396.
16. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624.
17. Van Thiel DH, Friedlander L, Kania RJ, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology 1997; 44: 808.
18. Ben-Ari Z, Shmueli D, Mor E, et al. Beneficial effect of lamivudine pre- and post-liver transplantation for hepatitis B infection. Transplant Proc 1997; 29: 268.
19. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212.
20. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65: 1615.
21. Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T cell depleted allogenic bone marrow transplantation. Hepatology 1993; 18: 256.
22. Flowers M, Sherker A, Sinclair SB, et al. Prostaglandin E in the treatment of recurrent hepatitis B infection after orthotopic liver transplantation. Transplantation 1994; 58: 183.
23. Marcellin P, Samuel D, Areias J, et al. Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. Hepatology 1994; 19: 6.
24. De la Mata M, Montero J, Fraga E, Gonzalez R, Pera C, Meno G. Efficacy of the gancyclovir in the treatment infection of the liver graft: long term results [Abstract]. Hepatology 1995; 22: 95A.
25. Singh N, Gayowski T. Lack of sustained efficacy of combination ganciclovir and foscarnet for hepatitis B virus recurrence after liver transplantation. Transplantation 1995; 59: 1629.
26. Gish RG, Lau JYN, Brooks L, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 1996; 23: 1.
27. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20.
28. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B: incidence and patterns. J Hepatol 1997; 26: 1393.
29. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585.
30. Kuhns MC, Mcnamara AL, Perillo RP, Cabal CM, Cambel CR. Quantitation of hepatitis B viral DNA by soluble hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Virol 1989; 27: 274.